Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, 6-Week, Parallel-design Study of the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy
NCT03304522 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-blind, Placebo-controlled, 6-Week, Parallel-design Study of the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 20, 2017
- Completion date
- November 8, 2018
- Enrollment
- 89 (actual)
- Sites
- 34
Conditions
As the registry lists them; a condition with its own page is linked.